ASCO 2017 | Results of a Phase III trial on CT-P6, a trastuzumab biosimilar candidate, in early breast cancer

Justin Stebbing • 4 Jun 2017

Breast Cancer CT-P6 Trastuzumab

Justin Stebbing, MD, PhD from Imperial College Healthcare NHS Trust, UK, presents results from a double-blind phase III study comparing the efficacy and safety of CT-P6, a trastuzumab biosimilar candidate, versus traztuzumab as neoadjuvant treatment in HER2-postivie early breast cancer.

Biosimilars: The future of treating breast cancer

Justin Stebbing • 2 Jun 2017

Developments in PD-1 and PD-L1 inhibitors presented at ASCO 2016

Justin Stebbing • 3 Jun 2016

Biosimilar trastuzumab: a cost effective alternative for breast cancer treatment

Justin Stebbing • 2 Jun 2017

The physician's role in prescribing biosimilars to patients

Justin Stebbing • 2 Jun 2017

Related Videos

What impact will biosimilars have on clinical life?

Diana Lüftner • 21 Sep 2017

How to manage elderly patients on immunotherapy

Matti Aapro • 18 Jan 2019

Highlights in breast and gynecological cancer at ESTRO 2022

Pedro Lara • 17 May 2022

IMpassion130 study: improvement in OS and PFS for IIT and PD-L1+ populations with mTNBC

Peter Schmid • 21 Oct 2018